Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EPS (Weighted Average and Diluted) (2016 - 2025)

Guided Therapeutics' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at -$0.01 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) changed 0.0% year-over-year to -$0.01; the TTM value through Sep 2025 reached -$0.05, down 25.0%, while the annual FY2024 figure was -$0.05, 28.57% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.01 at Guided Therapeutics, roughly flat from -$0.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.01 in Q3 2023 and bottomed at -$0.09 in Q2 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2023), against an average of -$0.03.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 82.73% in 2021 before it crashed 200.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.04 in 2021, then grew by 25.0% to -$0.03 in 2022, then surged by 66.67% to -$0.01 in 2023, then plummeted by 100.0% to -$0.02 in 2024, then surged by 50.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's EPS (Weighted Average and Diluted) are -$0.01 (Q3 2025), -$0.01 (Q2 2025), and -$0.01 (Q1 2025).